Left ventricular assist devices (LVAD) provide cardiac support for patients with end-stage
heart disease as either bridge or destination therapy, and have significantly improved the …

Aims Over decades, left ventricular assist device (LVAD) technology has transitioned from
less durable bulky pumps to smaller continuous‐flow pumps which have substantially …

Long-term mechanical circulatory support (LT-MCS) is an important treatment modality for
patients with severe heart failure. Different devices are available, and many—sometimes …

Background: The main risk factor for bleeding in patients with continuous-flow mechanical
circulatory support (CF-MCS) is the acquired von Willebrand factor (VWF) defect related to …

Aims Left ventricular assist device (LVAD) therapy improves the haemodynamics of
advanced heart failure patients. However, it is unknown whether haemodynamic …

Background: Angiotensin II receptor activation may result in angiogenesis, and ultimately
arteriovenous malformations (AVM), through transforming growth factor (TGF)-β and …

Background Left ventricular assist devices (LVADs) are an increasingly prevalent form of
mechanical support for patients with end-stage heart failure. These devices can be …

Background Aspirin (ASA) anti-platelet therapy is mandated with left ventricular assist
devices (LVADs) to prevent hemocompatibility-related adverse events (HRAEs). However …

Background: Gastrointestinal bleeding (GIB) is a leading cause of morbidity during
continuous-flow left ventricular assist device (CF-LVAD) support. GIB risk assessment could …

The medical management of patients supported with durable continuous flow left ventricular
assist device (LVAD) support encompasses pharmacological therapies administered in the …